Article(id=1329367096934380213, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367096166822579, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2025.01.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1720022400000, receivedDateStr=2024-07-04, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794875414354, onlineDateStr=2026-11-17, pubDate=1736438400000, pubDateStr=2025-01-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794875414354, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794875414354, creator=13701087609, updateTime=1794875414354, updator=13701087609, issue=Issue{id=1329367096166822579, tenantId=1146029695717560320, journalId=1319690259887390882, year='2025', volume='56', issue='1', pageStart='1', pageEnd='141', issueExtLink='null', onlineDate='null', pubDate='1736438400000', pubDateStr='2025-01-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794875414171, creator='13701087609', updateTime=1794887002143, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329415700000649272, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367096166822579, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329415700000649273, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367096166822579, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=28, endPage=37, ext={EN=ArticleExt(id=1329367097165066934, articleId=1329367096934380213, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Research Progress of Peptide-drug Conjugates, columnId=1327671169563603616, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Perspectives, runingTitle=null, highlight=null, articleAbstract=

Peptide-drug conjugates(PDCs) are emerging targeted drugs, composed of payloads, linkers, and homing peptides. By homing peptides, cytotoxic molecules or radionuclides can be enriched in cells of diseased tissues,thereby reducing the toxicity to normal cells. With the advantages of high selectivity, high tissue penetration, and low immunogenicity, PDCs have become a hot spot in the development of a new generation of targeted antineoplastic drugs following antibody-drug conjugates(ADCs). Nevertheless, PDCs still face some challenges, such as poor in vivo stability,and low receptor affinity. This paper reviews the composition, clinical application progress, key technologies, and challenges of PDCs, aiming to provide some references for the development and application of PDCs.

, authors=Jiahui XU1, Jun XU1, 2, Jianguang LU1, 2, *, authorsList=Jiahui XU, Jun XU, Jianguang LU, authorCompany=null, correspAuthors=Jianguang LU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329367097840349879, articleId=1329367096934380213, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=多肽偶联药物的研究进展, columnId=1327671169823650466, journalTitle=中国医药工业杂志, columnName=专论, runingTitle=null, highlight=null, articleAbstract=

多肽偶联药物(PDCs)是一种新兴的靶向药物,由有效载荷、连接子和归巢肽组成。归巢肽能携带细胞毒性分子或放射性核素向病变组织中的细胞富集,从而降低对正常细胞的毒性。凭借高选择性、高组织穿透性和低免疫原性等优势,PDCs成为了继抗体偶联药物(ADCs)后新一代靶向抗肿瘤药开发的关注热点。然而,PDCs仍面临着一些挑战,如体内稳定性差、受体亲和力低等。文章就PDCs的组成、临床应用进展以及关键性技术和挑战进行了综述,以期为PDCs的开发和应用提供参考。

, authors=徐佳慧1, 许俊1, 2, 路建光1, 2, *, authorsList=徐佳慧, 许俊, 路建光, authorCompany=null, correspAuthors=路建光, authorNote=

徐佳慧(1999—),女,硕士研究生,专业方向:微生物与生化药学。

, correspAuthorsNote=
路建光(1986—),男,研究员,博士,从事多肽与蛋白质药物的创新与产业开发。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=qmV6GDrvQuCz7HiM4tah0w==, magXml=74InVvkxYG18PN/QjlxDfQ==, pdfUrl=null, pdf=dwgpg4qHUHCLTAQtDuzOuA==, pdfFileSize=4518139, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=8wCOuwEAldmJfkofpYmK0g==, mapNumber=null, fund=null)}, authors=[Author(id=1329367098230420159, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367098310111937, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098230420159, language=EN, stringName=Jiahui XU, firstName=Jiahui, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367098402386626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098230420159, language=CN, stringName=徐佳慧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院,上海 201203, bio={"content":"

徐佳慧(1999—),女,硕士研究生,专业方向:微生物与生化药学。

"}, bioImg=null, bioContent=

徐佳慧(1999—),女,硕士研究生,专业方向:微生物与生化药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367098058453688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=1., ext=[AuthorCompanyExt(id=1329367098071036601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329367098083619514, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)])]), Author(id=1329367098469495492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367098553381575, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098469495492, language=EN, stringName=Jun XU, firstName=Jun, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203
2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367098612101832, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098469495492, language=CN, stringName=许俊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国医药工业研究总院,上海 201203
2.上海多米瑞生物技术有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367098058453688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=1., ext=[AuthorCompanyExt(id=1329367098071036601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329367098083619514, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1329367098146534075, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=2., ext=[AuthorCompanyExt(id=1329367098154922684, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367098163311293, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海多米瑞生物技术有限公司,上海 201203)])]), Author(id=1329367098687599306, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=lujgdmr@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329367098771485389, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098687599306, language=EN, stringName=Jianguang LU, firstName=Jianguang, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203
2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367098846982862, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098687599306, language=CN, stringName=路建光, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.中国医药工业研究总院,上海 201203
2.上海多米瑞生物技术有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367098058453688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=1., ext=[AuthorCompanyExt(id=1329367098071036601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329367098083619514, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1329367098146534075, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=2., ext=[AuthorCompanyExt(id=1329367098154922684, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367098163311293, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海多米瑞生物技术有限公司,上海 201203)])])], keywords=[Keyword(id=1329367098943451855, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=EN, orderNo=1, keyword=peptide-drug conjugate), Keyword(id=1329367099002172112, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=EN, orderNo=2, keyword=target), Keyword(id=1329367099073475281, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=EN, orderNo=3, keyword=homing peptide), Keyword(id=1329367099148972754, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=EN, orderNo=4, keyword=antineoplastics), Keyword(id=1329367099216081619, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=EN, orderNo=5, keyword=drug delivery), Keyword(id=1329367099287384788, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=EN, orderNo=6, keyword=research progress), Keyword(id=1329367099358687957, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=CN, orderNo=1, keyword=多肽偶联药物), Keyword(id=1329367099425796822, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=CN, orderNo=2, keyword=靶向), Keyword(id=1329367099488711383, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=CN, orderNo=3, keyword=归巢肽), Keyword(id=1329367099555820248, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=CN, orderNo=4, keyword=抗肿瘤药), Keyword(id=1329367099622929113, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=CN, orderNo=5, keyword=药物递送), Keyword(id=1329367099727786714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, language=CN, orderNo=6, keyword=研究进展)], refs=[Reference(id=1329367099937501916, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=SIEGEL R L, GIAQUINTO A N, JEMAL A.Cancer statistics, 2024 [J].CA Cancer J Clin, 2024, 74(1): 12-49., articleTitle=null, refAbstract=null), Reference(id=1329367100038165213, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=郭立红, 王金朋, 翟立海, 等.抗体偶联药物和小分子偶联药物的研究进展[J].中国医药工业杂志, 2019, 50(8):842-851., articleTitle=null, refAbstract=null), Reference(id=1329367100096885470, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=WU M, HUANG W, YANG N, et al.Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy [J].Exp Hematol Oncol, 2022, 11(1): 93., articleTitle=null, refAbstract=null), Reference(id=1329367100163994335, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=COOPER B M, IEGRE J, O’DONOVAN D H, et al.Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates(PDCs) [J].Chem Soc Rev, 2021, 50(3): 1480-1494., articleTitle=null, refAbstract=null), Reference(id=1329367100239491808, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=DENG X, MAI R Y, ZHANG C Y, et al.Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate(PDC) for programmable delivery of paclitaxel and cancer treatment [J].Eur J Med Chem, 2021, 213: 113050., articleTitle=null, refAbstract=null), Reference(id=1329367100298212065, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG M D, HOU D Y, LV G T, et al.Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency [J].Biomaterials, 2021, 278: 121139., articleTitle=null, refAbstract=null), Reference(id=1329367100361126626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU J Q, LI Y Y, HUANG W L, et al.Source and exploration of the peptides used to construct peptide-drug conjugates [J].Eur J Med Chem, 2021, 224: 113712., articleTitle=null, refAbstract=null), Reference(id=1329367100432429795, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=GHALY H S A, VARAMINI P.New drug delivery strategies targeting the GnRH receptor in breast and other cancers [J].Endocr Relat Cancer, 2021, 28(11): R251-R269., articleTitle=null, refAbstract=null), Reference(id=1329367100503732964, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=HU Y H, YE Z, WANG F, et al.Role of somatostatin receptor(SSTR) in pancreatic neuroendocrine tumor development,diagnosis and therapy [J].Front Endocrinol (Lausanne),2021, 12: 679000., articleTitle=null, refAbstract=null), Reference(id=1329367100570841829, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=CAI Y, ZHU B Y, SHAN X T, et al.Inhibiting endothelial cell-mediated T lymphocyte apoptosis with integrin‐targeting peptide‐drug conjugate filaments for chemoimmunotherapy of triple‐negative breast cancer [J].Adv Mater, 2024,36(3): e2306676., articleTitle=null, refAbstract=null), Reference(id=1329367100646339302, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=WU H C, FENG Y, SONG X Y, et al.Implantable polyurethane scaffolds loading with PEG-Paclitaxel conjugates for the treatment of glioblastoma multiforme [J]. Chin J Polym Sci, 2022, 40(5): 491-503., articleTitle=null, refAbstract=null), Reference(id=1329367100709253863, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM M S, MA S L, CHELARIU-RAICU A, et al.Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer [J].Mol Cancer Ther, 2020, 19(11): 2396-2406., articleTitle=null, refAbstract=null), Reference(id=1329367100767974120, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=CHELARIU-RAICU A, NICK A, URBAN R, et al.A multicenter open-label randomized phase Ⅱ trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer [J].Gynecol Oncol, 2021, 160(2):418-426., articleTitle=null, refAbstract=null), Reference(id=1329367100835082985, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=SINGH S, HALPERIN D, MYREHAUG S, et al.[177Lu] Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2 – 3, well-differentiated,gastroenteropancreatic neuroendocrine tumours(NETTER-2):an open-label, randomised, phase 3 study [J].Lancet, 2024,403(10446): 2807-2817., articleTitle=null, refAbstract=null), Reference(id=1329367100948329194, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=TAMMAM S N, AZZAZY H M E, LAMPRECHT A, et al.Nuclear and cytoplasmic delivery of lactoferrin in glioma using chitosan nanoparticles: cellular location dependent-action of lactoferrin [J].Eur J Pharm Biopharm, 2018, 129:74-79., articleTitle=null, refAbstract=null), Reference(id=1329367101036409579, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=KUMTHEKAR P, TANG S C, BRENNER A J, et al.ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases [J].Clin Cancer Res, 2020, 26(12): 2789-2799., articleTitle=null, refAbstract=null), Reference(id=1329367101116101356, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=PARK S E, SAJID M I, PARANG K, et al.Cyclic cell-penetrating peptides as efficient intracellular drug delivery tools [J].Mol Pharm, 2019, 16(9): 3727-3743., articleTitle=null, refAbstract=null), Reference(id=1329367101179015917, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=MCKEAN M, FALCHOOK G S, BENDELL J C, et al.Association of combined phaseⅠ/Ⅱ study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with nectin-4 expression [J].J Clin Oncol, 2021, 39(15 Suppl): TPS2668., articleTitle=null, refAbstract=null), Reference(id=1329367101246124782, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=WU L Y, SHEN L, HU X C, et al.A phase Ⅰa/Ⅰb study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors [J].J Clin Oncol, 2022, 40(16 Suppl): 3000., articleTitle=null, refAbstract=null), Reference(id=1329367101309039343, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=XUE Y Y, YE X C, WEI L S, et al.Better performance with transformer: CPPFormer in the precise prediction of cell-penetrating peptides [J].Curr Med Chem, 2022, 29(5): 881-893., articleTitle=null, refAbstract=null), Reference(id=1329367101376148208, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=DHILLON S.Melphalan flufenamide (melflufen): first approval [J].Drugs, 2021, 81(8): 963-969., articleTitle=null, refAbstract=null), Reference(id=1329367101451645681, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHU Z C, ZHAI Y X, HAO Y, et al.Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides[J].J Extracell Vesicles, 2022, 11(8): e12255., articleTitle=null, refAbstract=null), Reference(id=1329367101531337458, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=MERIC-BERNSTAM F, EDER J, VANDROSS A, et al.CBX-12-101: a first-in-human study of CBX-12, an alphalex peptide drug conjugate(PDC) in patients with advanced or metastatic solid tumors [J].Eur J Cancer, 2022, 174(1 Suppl): S7-S8., articleTitle=null, refAbstract=null), Reference(id=1329367101598446323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=CHENG D B, WANG D, GAO Y J, et al.Autocatalytic morphology transformation platform for targeted drug accumulation [J].J Am Chem Soc, 2019, 141(10): 4406-4411., articleTitle=null, refAbstract=null), Reference(id=1329367101699109620, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=VRETTOS E I, KARAMPELAS T, SAYYAD N, et al.Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable “click” oxime bond tethers and preclinical evaluation against prostate cancer [J].Eur J Med Chem, 2021, 211: 113018., articleTitle=null, refAbstract=null), Reference(id=1329367101770412789, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=SU Z, XIAO D, XIE F, et al.Antibody-drug conjugates:recent advances in linker chemistry [J].Acta Pharm Sin B,2021, 11(12): 3889-3907., articleTitle=null, refAbstract=null), Reference(id=1329367101841715958, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=ĐORĐEVIĆ S, MEDEL M, HILLAERT J, et al.Critical design strategies supporting optimized drug release from polymer-drug conjugates [J].Small, 2024, 20(4): e2303157., articleTitle=null, refAbstract=null), Reference(id=1329367101904630519, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=MILLER D S, SCAMBIA G, BONDARENKO I, et al.ZoptEC: phaseⅢ randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer(NCT01767155) [J].J Clin Oncol, 2018, 36(15 Suppl): 5503., articleTitle=null, refAbstract=null), Reference(id=1329367101975933688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=MUTTENTHALER M, KING G F, ADAMS D J, et al.Trends in peptide drug discovery [J].Nat Rev Drug Discov,2021, 20(4): 309-325., articleTitle=null, refAbstract=null), Reference(id=1329367102038848249, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=HAN Y, GAO Z G, CHEN L Q, et al.Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins [J].Acta Pharm Sin B, 2019, 9(5): 902-922., articleTitle=null, refAbstract=null), Reference(id=1329367102126928634, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=DRUCKER D J.Advances in oral peptide therapeutics [J].Nat Rev Drug Discov, 2020, 19(4): 277-289., articleTitle=null, refAbstract=null), Reference(id=1329367102198231803, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=ARODA V R, BLONDE L, PRATLEY R E, et al.A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes [J].Rev Endocr Metab Disord, 2022, 23(5): 979-994., articleTitle=null, refAbstract=null), Reference(id=1329367102256952060, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=CHOW H Y, ZHANG Y, MATHESON E, et al.Ligation technologies for the synthesis of cyclic peptides [J].Chem Rev, 2019, 119(17): 9971-10001., articleTitle=null, refAbstract=null), Reference(id=1329367102328255229, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=LI Y L, WU M H, FU Y X, et al.Therapeutic stapled peptides: efficacy and molecular targets [J].Pharmacol Res,2024, 203: 107137., articleTitle=null, refAbstract=null), Reference(id=1329367102382781182, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=WU X, GUO H, GAO H, et al.Peptide targeting improves the delivery and therapeutic index of glucocorticoids to treat rheumatoid arthritis [J].J Control Release, 2024, 368: 329-343., articleTitle=null, refAbstract=null), Reference(id=1329367102445695743, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=NAZLI A, HE D L, LIAO D D, et al.Strategies and progresses for enhancing targeted antibiotic delivery [J].Adv Drug Deliv Rev, 2022, 189: 114502., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329367099841032923, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, awardId=22ZR14258000, language=CN, fundingSource=上海市自然科学基金项目(22ZR14258000), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329367098058453688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=1., ext=[AuthorCompanyExt(id=1329367098071036601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329367098083619514, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1329367098146534075, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=2., ext=[AuthorCompanyExt(id=1329367098154922684, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367098163311293, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海多米瑞生物技术有限公司,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2025.01.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2025.01.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2025.01.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2025.01.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1736438400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
多肽偶联药物的研究进展
徐佳慧 1 , 许俊 1, 2 , 路建光 1, 2, *
中国医药工业杂志 | 专论 2025,56(1): 28-37
收起
收藏切换
中国医药工业杂志 |专论 2025 , 56 (1) : 28 -37
多肽偶联药物的研究进展
全屏
[Author(id=1329367098230420159, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367098310111937, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098230420159, language=EN, stringName=Jiahui XU, firstName=Jiahui, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367098402386626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098230420159, language=CN, stringName=徐佳慧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院,上海 201203, bio={"content":"

徐佳慧(1999—),女,硕士研究生,专业方向:微生物与生化药学。

"}, bioImg=null, bioContent=

徐佳慧(1999—),女,硕士研究生,专业方向:微生物与生化药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367098058453688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=1., ext=[AuthorCompanyExt(id=1329367098071036601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329367098083619514, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)])]), Author(id=1329367098469495492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367098553381575, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098469495492, language=EN, stringName=Jun XU, firstName=Jun, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203
2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367098612101832, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098469495492, language=CN, stringName=许俊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国医药工业研究总院,上海 201203
2.上海多米瑞生物技术有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367098058453688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=1., ext=[AuthorCompanyExt(id=1329367098071036601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329367098083619514, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1329367098146534075, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=2., ext=[AuthorCompanyExt(id=1329367098154922684, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367098163311293, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海多米瑞生物技术有限公司,上海 201203)])]), Author(id=1329367098687599306, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=lujgdmr@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329367098771485389, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098687599306, language=EN, stringName=Jianguang LU, firstName=Jianguang, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203
2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367098846982862, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, authorId=1329367098687599306, language=CN, stringName=路建光, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.中国医药工业研究总院,上海 201203
2.上海多米瑞生物技术有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367098058453688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=1., ext=[AuthorCompanyExt(id=1329367098071036601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329367098083619514, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098058453688, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1329367098146534075, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, xref=2., ext=[AuthorCompanyExt(id=1329367098154922684, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367098163311293, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367096934380213, companyId=1329367098146534075, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海多米瑞生物技术有限公司,上海 201203)])])]
徐佳慧1, 许俊1, 2, 路建光1, 2, *
作者信息
  • 1.中国医药工业研究总院,上海 201203
  • 2.上海多米瑞生物技术有限公司,上海 201203
通讯作者:
路建光(1986—),男,研究员,博士,从事多肽与蛋白质药物的创新与产业开发。E-mail:
作者简介:

徐佳慧(1999—),女,硕士研究生,专业方向:微生物与生化药学。

Research Progress of Peptide-drug Conjugates
Jiahui XU1, Jun XU1, 2, Jianguang LU1, 2, *
Affiliations
  • 1.China State Institute of Pharmaceutical Industry, Shanghai 201203
  • 2.Shanghai Duomirui Bio-Technology Co., Ltd., Shanghai 201203
出版时间: 2025-01-10 doi: 10.16522/j.cnki.cjph.2025.01.002
文章导航
收藏切换

多肽偶联药物(PDCs)是一种新兴的靶向药物,由有效载荷、连接子和归巢肽组成。归巢肽能携带细胞毒性分子或放射性核素向病变组织中的细胞富集,从而降低对正常细胞的毒性。凭借高选择性、高组织穿透性和低免疫原性等优势,PDCs成为了继抗体偶联药物(ADCs)后新一代靶向抗肿瘤药开发的关注热点。然而,PDCs仍面临着一些挑战,如体内稳定性差、受体亲和力低等。文章就PDCs的组成、临床应用进展以及关键性技术和挑战进行了综述,以期为PDCs的开发和应用提供参考。

多肽偶联药物  /  靶向  /  归巢肽  /  抗肿瘤药  /  药物递送  /  研究进展

Peptide-drug conjugates(PDCs) are emerging targeted drugs, composed of payloads, linkers, and homing peptides. By homing peptides, cytotoxic molecules or radionuclides can be enriched in cells of diseased tissues,thereby reducing the toxicity to normal cells. With the advantages of high selectivity, high tissue penetration, and low immunogenicity, PDCs have become a hot spot in the development of a new generation of targeted antineoplastic drugs following antibody-drug conjugates(ADCs). Nevertheless, PDCs still face some challenges, such as poor in vivo stability,and low receptor affinity. This paper reviews the composition, clinical application progress, key technologies, and challenges of PDCs, aiming to provide some references for the development and application of PDCs.

peptide-drug conjugate  /  target  /  homing peptide  /  antineoplastics  /  drug delivery  /  research progress
徐佳慧, 许俊, 路建光. 多肽偶联药物的研究进展. 中国医药工业杂志, 2025 , 56 (1) : 28 -37 . DOI: 10.16522/j.cnki.cjph.2025.01.002
Jiahui XU, Jun XU, Jianguang LU. Research Progress of Peptide-drug Conjugates[J]. Chinese Journal of Pharmaceuticals, 2025 , 56 (1) : 28 -37 . DOI: 10.16522/j.cnki.cjph.2025.01.002
  • 上海市自然科学基金项目(22ZR14258000)
参考文献 引证文献
排序方式:
[1]
SIEGEL R L, GIAQUINTO A N, JEMAL A.Cancer statistics, 2024 [J].CA Cancer J Clin, 2024, 74(1): 12-49.
[2]
郭立红, 王金朋, 翟立海, 等.抗体偶联药物和小分子偶联药物的研究进展[J].中国医药工业杂志, 2019, 50(8):842-851.
[3]
WU M, HUANG W, YANG N, et al.Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy [J].Exp Hematol Oncol, 2022, 11(1): 93.
[4]
COOPER B M, IEGRE J, O’DONOVAN D H, et al.Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates(PDCs) [J].Chem Soc Rev, 2021, 50(3): 1480-1494.
[5]
DENG X, MAI R Y, ZHANG C Y, et al.Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate(PDC) for programmable delivery of paclitaxel and cancer treatment [J].Eur J Med Chem, 2021, 213: 113050.
[6]
WANG M D, HOU D Y, LV G T, et al.Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency [J].Biomaterials, 2021, 278: 121139.
[7]
ZHOU J Q, LI Y Y, HUANG W L, et al.Source and exploration of the peptides used to construct peptide-drug conjugates [J].Eur J Med Chem, 2021, 224: 113712.
[8]
GHALY H S A, VARAMINI P.New drug delivery strategies targeting the GnRH receptor in breast and other cancers [J].Endocr Relat Cancer, 2021, 28(11): R251-R269.
[9]
HU Y H, YE Z, WANG F, et al.Role of somatostatin receptor(SSTR) in pancreatic neuroendocrine tumor development,diagnosis and therapy [J].Front Endocrinol (Lausanne),2021, 12: 679000.
[10]
CAI Y, ZHU B Y, SHAN X T, et al.Inhibiting endothelial cell-mediated T lymphocyte apoptosis with integrin‐targeting peptide‐drug conjugate filaments for chemoimmunotherapy of triple‐negative breast cancer [J].Adv Mater, 2024,36(3): e2306676.
[11]
WU H C, FENG Y, SONG X Y, et al.Implantable polyurethane scaffolds loading with PEG-Paclitaxel conjugates for the treatment of glioblastoma multiforme [J]. Chin J Polym Sci, 2022, 40(5): 491-503.
[12]
KIM M S, MA S L, CHELARIU-RAICU A, et al.Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer [J].Mol Cancer Ther, 2020, 19(11): 2396-2406.
[13]
CHELARIU-RAICU A, NICK A, URBAN R, et al.A multicenter open-label randomized phase Ⅱ trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer [J].Gynecol Oncol, 2021, 160(2):418-426.
[14]
SINGH S, HALPERIN D, MYREHAUG S, et al.[177Lu] Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2 – 3, well-differentiated,gastroenteropancreatic neuroendocrine tumours(NETTER-2):an open-label, randomised, phase 3 study [J].Lancet, 2024,403(10446): 2807-2817.
[15]
TAMMAM S N, AZZAZY H M E, LAMPRECHT A, et al.Nuclear and cytoplasmic delivery of lactoferrin in glioma using chitosan nanoparticles: cellular location dependent-action of lactoferrin [J].Eur J Pharm Biopharm, 2018, 129:74-79.
[16]
KUMTHEKAR P, TANG S C, BRENNER A J, et al.ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases [J].Clin Cancer Res, 2020, 26(12): 2789-2799.
[17]
PARK S E, SAJID M I, PARANG K, et al.Cyclic cell-penetrating peptides as efficient intracellular drug delivery tools [J].Mol Pharm, 2019, 16(9): 3727-3743.
[18]
MCKEAN M, FALCHOOK G S, BENDELL J C, et al.Association of combined phaseⅠ/Ⅱ study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with nectin-4 expression [J].J Clin Oncol, 2021, 39(15 Suppl): TPS2668.
[19]
WU L Y, SHEN L, HU X C, et al.A phase Ⅰa/Ⅰb study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors [J].J Clin Oncol, 2022, 40(16 Suppl): 3000.
[20]
XUE Y Y, YE X C, WEI L S, et al.Better performance with transformer: CPPFormer in the precise prediction of cell-penetrating peptides [J].Curr Med Chem, 2022, 29(5): 881-893.
[21]
DHILLON S.Melphalan flufenamide (melflufen): first approval [J].Drugs, 2021, 81(8): 963-969.
[22]
ZHU Z C, ZHAI Y X, HAO Y, et al.Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides[J].J Extracell Vesicles, 2022, 11(8): e12255.
[23]
MERIC-BERNSTAM F, EDER J, VANDROSS A, et al.CBX-12-101: a first-in-human study of CBX-12, an alphalex peptide drug conjugate(PDC) in patients with advanced or metastatic solid tumors [J].Eur J Cancer, 2022, 174(1 Suppl): S7-S8.
[24]
CHENG D B, WANG D, GAO Y J, et al.Autocatalytic morphology transformation platform for targeted drug accumulation [J].J Am Chem Soc, 2019, 141(10): 4406-4411.
[25]
VRETTOS E I, KARAMPELAS T, SAYYAD N, et al.Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable “click” oxime bond tethers and preclinical evaluation against prostate cancer [J].Eur J Med Chem, 2021, 211: 113018.
[26]
SU Z, XIAO D, XIE F, et al.Antibody-drug conjugates:recent advances in linker chemistry [J].Acta Pharm Sin B,2021, 11(12): 3889-3907.
[27]
ĐORĐEVIĆ S, MEDEL M, HILLAERT J, et al.Critical design strategies supporting optimized drug release from polymer-drug conjugates [J].Small, 2024, 20(4): e2303157.
[28]
MILLER D S, SCAMBIA G, BONDARENKO I, et al.ZoptEC: phaseⅢ randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer(NCT01767155) [J].J Clin Oncol, 2018, 36(15 Suppl): 5503.
[29]
MUTTENTHALER M, KING G F, ADAMS D J, et al.Trends in peptide drug discovery [J].Nat Rev Drug Discov,2021, 20(4): 309-325.
[30]
HAN Y, GAO Z G, CHEN L Q, et al.Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins [J].Acta Pharm Sin B, 2019, 9(5): 902-922.
[31]
DRUCKER D J.Advances in oral peptide therapeutics [J].Nat Rev Drug Discov, 2020, 19(4): 277-289.
[32]
ARODA V R, BLONDE L, PRATLEY R E, et al.A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes [J].Rev Endocr Metab Disord, 2022, 23(5): 979-994.
[33]
CHOW H Y, ZHANG Y, MATHESON E, et al.Ligation technologies for the synthesis of cyclic peptides [J].Chem Rev, 2019, 119(17): 9971-10001.
[34]
LI Y L, WU M H, FU Y X, et al.Therapeutic stapled peptides: efficacy and molecular targets [J].Pharmacol Res,2024, 203: 107137.
[35]
WU X, GUO H, GAO H, et al.Peptide targeting improves the delivery and therapeutic index of glucocorticoids to treat rheumatoid arthritis [J].J Control Release, 2024, 368: 329-343.
[36]
NAZLI A, HE D L, LIAO D D, et al.Strategies and progresses for enhancing targeted antibiotic delivery [J].Adv Drug Deliv Rev, 2022, 189: 114502.
2025年第56卷第1期
40
11
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2025.01.002
  • 接收时间:2024-07-04
  • 首发时间:2026-11-17
  • 出版时间:2025-01-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-07-04
基金
上海市自然科学基金项目(22ZR14258000)
作者信息
    1.中国医药工业研究总院,上海 201203
    2.上海多米瑞生物技术有限公司,上海 201203

通讯作者:

路建光(1986—),男,研究员,博士,从事多肽与蛋白质药物的创新与产业开发。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2025.01.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏